Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1979 Feb;34(1):68–73. doi: 10.1136/thx.34.1.68

Cell-mediated immunity in operable bronchial carcinoma: the effect of injecting irradiated autologous tumour cells and BCG.

B H Stack, N McSwan, J M Stirling, D J Hole, D Parratt, W G Spilg, C R Gillis, I McHattie, A G Green, R G White, M A Turner
PMCID: PMC471010  PMID: 442002

Abstract

In 52 patients undergoing tests of cell-mediated immunity before surgical resection of bronchial carcinoma a positive tuberculin test result was found in 71% compared with 68% of age- and sex-matched controls. Sensitisation to DNCB occurred in 52% of 37 patients but in 78% of controls. There was depression of lymphocyte transformation by PPD in 19 patients compared with controls (P=0.001), but there was no difference in lymphocyte transformation by PHA or pokeweed mitogen between 34 patients and controls. In a pilot study patients were randomly allocated to autograft (eight) or non-autograft (seven) groups. The autograft group were given an intradermal injection of a suspension of irradiated autologous tumour-cells mixed with intradermal BCG on the day of operation. Tests of cell-mediated immunity were repeated two weeks after operation. Five patients in each group received a course of radiotherapy to the mediastinum three weeks after operation. There was a rise in cutaneous tuberculin reactivity (P=0.08) and total leucocyte count (P=0.09) in the autograft group postoperatively with a fall in total lymphocyte and T lymphocyte counts in the non-autograft group (P less 0.05). These differences, however, were not followed by any difference in the frequency of tumour recurrence or the survival rate two years after operation. The results show that the immunological surveillance mechanism is impaired even in patients with early bronchial carcinoma and that it is possible to overcome postoperative immunological depression with specific immunotherapy combined with BCG. This treatment did not produce any clinical advantage in this small number of patients and the skin lesions caused the patients considerable discomfort.

Full text

PDF
68

Images in this article

71Image
on p.71
71Image
on p.71

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. M., Kelly F., Wood S. E., Rodger K. D., Freshney R. I. Evaluation of leucocyte functions six years after tumour autograft in human mammary cancer. Br J Cancer Suppl. 1973 Aug;1:83–96. [PMC free article] [PubMed] [Google Scholar]
  2. Bancewicz J., Gray A. C., Lindop G. The immunosuppressive effect of surgery--a possible mechanism. Br J Surg. 1973 Apr;60(4):314–315. [PubMed] [Google Scholar]
  3. Barnes E. W., Farmer A., Penhale W. J., Irvine W. J., Roscoe P., Horne N. W. Phytohemagglutinin-induced lymphocyte transformation in newly presenting patients with primary carcinoma of the lung. Cancer. 1975 Jul;36(1):187–193. doi: 10.1002/1097-0142(197507)36:1<187::aid-cncr2820360117>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  4. Coy P., Thomas J. W., Hasham N. Lymphocyte transformation in lung cancer patients. J Can Assoc Radiol. 1977 Mar;28(1):43–48. [PubMed] [Google Scholar]
  5. Dellon A. L., Potvin C., Chretien P. B. Thymus-dependent lymphocyte levels in bronchogenic carcinoma: correlations with histology, clinical stage, and clinical course after surgical treatment. Cancer. 1975 Mar;35(3):687–694. doi: 10.1002/1097-0142(197503)35:3<687::aid-cncr2820350322>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  6. Edwards F. R., Whitwell F. Use of BCG as an immunostimulant in the surgical treatment of carcinoma of lung: a five-year follow-up report. Thorax. 1978 Apr;33(2):250–252. doi: 10.1136/thx.33.2.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Evans D. A. Immunology of bronchial carcinoma. Thorax. 1976 Oct;31(5):493–506. doi: 10.1136/thx.31.5.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gross N. J., Eddie-Quartey A. C. Monitoring of immunologic status of patients receiving BCG therapy for malignant disease. Cancer. 1976 May;37(5):2183–2193. doi: 10.1002/1097-0142(197605)37:5<2183::aid-cncr2820370505>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  9. Holmes E. C., Golub S. H. Immunologic defects in lung cancer patients. J Thorac Cardiovasc Surg. 1976 Feb;71(2):161–168. [PubMed] [Google Scholar]
  10. MacKie R., Sless F. R., Cochran R., De Sousa M. Lymphocyte abnormalities in mycosis fungoides. Br J Dermatol. 1976 Feb;94(2):173–178. doi: 10.1111/j.1365-2133.1976.tb04367.x. [DOI] [PubMed] [Google Scholar]
  11. McKneally M. F., Maver C., Kausel H. W. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet. 1976 Feb 21;1(7956):377–379. doi: 10.1016/s0140-6736(76)90212-9. [DOI] [PubMed] [Google Scholar]
  12. Park S. K., Brody J. I., Wallace H. A., Blakemore W. S. Immunosuppressive effect of surgery. Lancet. 1971 Jan 9;1(7689):53–55. doi: 10.1016/s0140-6736(71)90777-x. [DOI] [PubMed] [Google Scholar]
  13. Weese J. L., Herberman R. B., Perlin E., Mills M., Heims W., Blom J., Green D., Reid J., Bellinger S., Law I. Immunological monitoring and immunotherapy in carcinoma of the lung. Int J Cancer. 1976 Dec 15;18(6):739–749. doi: 10.1002/ijc.2910180604. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES